Repaglinide with Metformin

Repaglinide with Metformin is a combination medication used to treat type 2 diabetes. It contains two active ingredients, repaglinide and metformin, which work together to help control blood sugar levels.

Indications

This combination is indicated for the management of type 2 diabetes mellitus in adults, particularly when diet and exercise alone do not provide adequate glycemic control. It is usually prescribed when both repaglinide and metformin are deemed necessary for effective blood glucose management.

Dosage

Dosage should be individualized based on the patient's response and tolerance. Typically, it is taken orally with meals. The dosage may vary, and it is crucial to follow the healthcare provider's recommendations.

Contra-Indications

-Hypersensitivity to repaglinide, metformin, or any components of the medication. -Severe renal impairment. -Hepatic dysfunction. -Concomitant use with gemfibrozil.

Special Precautions

-Regular monitoring of blood glucose levels is essential. -Caution in patients with renal impairment; dosage adjustments may be required. -Liver function should be monitored regularly. -Discontinue use if lactic acidosis symptoms occur (e.g., malaise, myalgia, respiratory distress).

Side Effects

Common side effects may include hypoglycemia, gastrointestinal disturbances (nausea, diarrhea), and weight gain. Less common but more severe side effects may include lactic acidosis, hepatotoxicity, and allergic reactions.

Drug Interactions

-Increased risk of hypoglycemia when combined with other antidiabetic agents. -Potential interactions with certain drugs affecting renal function. -Enhanced effects with concurrent use of drugs affecting hepatic metabolism.